FDA Announces Recall of Propofol Injectable Emulsion by Hospira: AttorneyOne Monitor and Keep Consumers Informed

On April 18, the FDA announced the nationwide recall of seven lots of Propofol Injectable Emulsion, 1%, 200 mg/20 mL (10 mg/mL) by Hospira due to a glass defect. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
Propofol Recall

Propofol Recall

Customers have been advised to check inventory and immediately quarantine any affected product

San Diego, CA (PRWEB) April 22, 2014

AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for drugs including Propofol.

As the FDA announced on April 18, seven lots of Propofol Injectable Emulsion, 1%, 200 mg/20 mL (10 mg/mL) by Hospira due to a glass defect as during a sample inspection the glass vial contained visible embedded metal particulate.

If particulate matter is injected, it may cause local inflammation, phlebitis, and/or low level allergic response through mechanical disruption of tissue or immune response to the particulate. It may also lead to granulomatous formation. In extremely rare cases, this may put patients at risk from MRI as particulate, if in the lung, could dislodge and be pulled through tissue.

The affected lots are: 29-614-DJ, 29-615-DJ, 29-616-DJ, 29-617-DJ, 29-628-DJ, 29-629-DJ, 29-630-DJ, and their distribution dates were from August 2013 to December 2013.

Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds “we are determined to keep an eye on FDA announcements concerning Propofol and inform the public. For that reason", he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”

As the FDA recommends “Customers have been advised to check inventory and immediately quarantine any affected product. In addition, customers should inform potential users of this product in their organizations of this notification.”

AttorneyOne.com has further information on Propofol at the website including latest major drug and medical products law news.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/04/prweb11778989.htm